Olema Pharmaceuticals Inc
$ 24.69
1.35%
24 Feb - close price
- Market Cap 1,979,148,000 USD
- Current Price $ 24.69
- High / Low $ 25.20 / 23.66
- Stock P/E N/A
- Book Value 4.48
- EPS -1.76
- Next Earning Report 2026-03-17
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.34 %
- ROE -0.59 %
- 52 Week High 36.26
- 52 Week Low 2.86
About
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company is headquartered in San Francisco, California.
Analyst Target Price
$46.09
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-11 | 2025-05-06 | 2025-03-10 | 2024-11-05 | 2024-08-06 | 2024-05-08 | 2024-03-11 | 2023-11-07 | 2023-08-08 | 2023-05-09 | 2023-03-09 |
| Reported EPS | -0.49 | -0.51 | -0.36 | -0.51 | -0.6 | -0.54 | -0.56 | -0.49 | -0.48 | -0.49 | -0.7 | -0.65 |
| Estimated EPS | -0.4702 | -0.38 | -0.55 | 0.1732 | -0.58 | -0.55 | -0.55 | -0.48 | -0.51 | -0.73 | -0.66 | -0.65 |
| Surprise | -0.0198 | -0.13 | 0.19 | -0.6832 | -0.02 | 0.01 | -0.01 | -0.01 | 0.03 | 0.24 | -0.04 | 0 |
| Surprise Percentage | -4.211% | -34.2105% | 34.5455% | -394.4573% | -3.4483% | 1.8182% | -1.8182% | -2.0833% | 5.8824% | 32.8767% | -6.0606% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-17 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.51 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: OLMA
2026-02-24 09:52:11
Olema Pharmaceuticals CEO Sean Bohen highlighted the company's progress on its lead drug palazestrant, which is in two Phase 3 trials for ER-positive, HER2-negative breast cancer. He also provided updates on the early-stage oral KAT6 inhibitor program, OP-3136, with monotherapy updates expected in late Q2. The company plans a potential U.S. filing for palazestrant if OPERA-01 trials are positive and is seeking partners for ex-U.S. markets.
2026-02-20 17:01:24
Olema Oncology will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026. Sean P. Bohen, M.D., Ph.D., President and CEO, will provide an update on the company's clinical-stage biopharmaceutical pipeline, which focuses on targeted therapies for breast cancer. A live webcast of the presentation will be available on Olema's investor relations website.
2026-02-20 16:40:31
Olema Oncology (Nasdaq: OLMA) announced that CEO Sean P. Bohen will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 2:30 p.m. ET. A live webcast will be available on the company's investor relations website. The presentation is expected to provide a company update, including program progress and corporate developments, with the stock reacting positively to the news.
2026-02-18 00:27:41
Stifel has initiated coverage on Olema Pharmaceuticals (OLMA) with a "buy" rating. This indicates a positive outlook from the investment bank regarding the company's stock. Further details on the price target or specific reasons for the rating are not available in this brief update.
2026-02-16 01:57:14
The biotech sector is seeing significant stock surges and advancements, with companies like Olema Pharmaceuticals reaching new 52-week highs due to positive trial results and strategic offerings. Wall Street analysts forecast a rise in OLMA stock price, initiating "Buy" ratings based on the strong market opportunity for its lead asset, palazestrant, in breast cancer treatment. Investors are also considering options contracts for OLMA, highlighting potential yield and return opportunities, alongside discussions of recent executive changes and the company's financial stability.
2026-02-14 18:07:56
Olema Pharmaceuticals CEO Sean Bohen provided updates on the company's pipeline, including an expected Fall readout for the OPERA-01 trial of palazestrant and Q2 2026 data for the KAT6 inhibitor OP-3136. Bohen also addressed the departure of CFO/COO Shane Kovacs, framing it as the company prepares for potential commercialization of palazestrant in the U.S. and seeks ex-U.S. partners. He emphasized palazestrant's potential as a best-in-class oral SERD, citing its pharmacologic attributes and past clinical results.
